David Chung
The University of Hong Kong · The Universtiy of Hong Kong · Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Chung as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:22 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT04200586 · The Effects of SGLTi on Diabetic CardiomyopathyThe University of Hong Kong · unknown · Type2 Diabetes, Heart Failure With Reduced Ejection Fraction · principal investigator
- N/ANCT03446339 · Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE)The University of Hong Kong · unknown · Connective Tissue Diseases, Systemic Sclerosis, Systemic Lupus Erythematosus · principal investigator
- Ph1NCT01995708 · CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationMemorial Sloan Kettering Cancer Center · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:22 UTC. The ranking covers the 200 most relevant of 117 PubMed records, and a shared surname and initials can bring in a namesake. All 117 on PubMed
- 1,606 citationsRCR 60.2
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.Nat Med · 20041,549 citationsRCR 31.8
- 961 citationsRCR 29.7
- Celecoxib for the prevention of sporadic colorectal adenomas.N Engl J Med · 2006843 citationsRCR 18.7
- Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.Lancet · 2009695 citationsRCR 16.9
- Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.J Clin Oncol · 2005641 citationsRCR 13.1
- Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.J Clin Oncol · 2009408 citationsRCR 9.3
- 391 citationsRCR 14.1
- Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.Ophthalmology · 2019345 citationsRCR 16.0
- AAV2 gene therapy readministration in three adults with congenital blindness.Sci Transl Med · 2012334 citationsRCR 9.7